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Animal models have been proven to be a crucial tool for investigating the physiological 
mechanisms underlying bariatric surgery in general and individual techniques in partic-
ular. By using a translational approach, most of these studies have been performed in 
rodents and have helped to understand how bariatric surgery may or may not work. 
However, data from studies using animal models should always be critically evaluated 
for their transferability to the human physiology. It is, therefore, the aim of this review to 
summarize both advantages and limitations of data generated by animal based experi-
ments designed to investigate and understand the physiological mechanisms at the root 
of bariatric surgery.
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iNTRODUCTiON
Obesity and its related comorbidities have detrimental effects for the affected individual and pose a 
major challenge on public health systems worldwide. Despite the availability of a number of phar-
macotherapies, the best treatment option leading to clinically relevant and maintained body weight 
loss is bariatric surgery (1–6). Bariatric surgery leads to a long-term reduction in body weight and 
in obesity-related morbidity and is currently the only treatment modality with a proven mortality 
benefit (4). Several techniques are currently employed. The gold-standard since many years is the 
Roux-en-Y gastric bypass (RYGB), followed by vertical sleeve gastrectomy (VSG) and, with decreas-
ing numbers, adjustable gastric banding (AGB); the so-called mini-gastric bypass (MGB) has gained 
some popularity recently.
The treatment success of RYGB appears to be associated at least in part with changes in gastro-
intestinal hormones and bile acids that have been found to exert some role in the control of eating 
(7, 8). Despite the very different surgical approach, RYGB and VSG are associated with some extent 
with similar hormonal changes (9, 10). By contrast, reduced eating and weight loss after AGB is 
generally thought to result rather from mechanical restriction due to the reduced filling capacity 
of the stomach, although recent animal data suggest some role for gastrointestinal hormones, too 
(11). The MGB has been introduced ~20 years ago and has gained some popularity, in particular in 
non-academic surgical centers. However, surprisingly little research has been performed to study the 
underlying mechanisms that lead to body weight loss after MGB (12, 13).
Animal models have been proven to be a crucial tool for investigating the physiological mecha-
nisms underlying bariatric surgery in general and individual techniques in particular. By using a 
translational approach, most of these studies have been performed in rodents and have helped to 
understand how bariatric surgery may or may not work. However, data from studies using animal 
models should always be critically evaluated for their transferability to the human physiology. It is, 
therefore, the aim of this review to summarize both advantages and limitations of data generated by 
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animal-based experiments designed to investigate and understand 
the physiological mechanisms at the root of bariatric surgery.
ROLe OF BARiATRiC SURGeRY iN ANTi-
OBeSiTY THeRAPY
The number of non-surgical options to treat obesity are limited 
and the long-term success of dietary or life style interventions 
is minimal (2, 14). New drugs have recently been approved for 
obesity treatment, but long-term data are not available yet (1, 6). 
Insights into mechanisms of bariatric surgery, in particular RYGB 
and VSG, have opened up new treatment avenues against obe-
sity. Among these, gut hormone-based strategies represent the 
most promising approach and are mainly focused on analogs of 
glucagon-like peptide-1 (GLP-1), such as liraglutide (Saxenda®) 
(15, 16). However, combinations of different hormones, such as 
amylin and leptin analogs, have also delivered remarkable results 
(17, 18).
However, due to an enormous discrepancy between the 
number of performed bariatric interventions, on the one hand, 
and the number of formally eligible patients worldwide, on the 
other hand [e.g., a number of ~0.5 Mio operations worldwide 
performed in 2013 (19) compares to the number of obese indi-
viduals of about 100 Mio in the USA alone (20–22)], it is obvious 
that the obesity epidemic cannot be successfully addressed by 
surgical means alone and that other non-surgical methods with 
a similar or superior efficacy and safety profile are urgently 
needed.
In this regard, research with animal models has significantly 
helped to elucidate some of the potential mechanisms underlying 
bariatric surgery. In comparison to human studies where investi-
gating food intake is predominantly reliant on verbal report and 
dietary recall measures of patients, animal experiments allow the 
assessment of objective and unbiased data regarding postopera-
tive changes of food intake. Furthermore, employment of genetic 
knockout models or specific antibodies directed against specific 
gut hormones or their receptors can only be performed in animals 
and have, thus, helped to differentiate between associative and 
causative relationships of proposed mechanisms of bariatric sur-
gery. However, it needs to be emphasized that neither qualitative 
nor quantitative data generated in animals should be extrapolated 
to the human setting “one-to-one” and that animal studies unfold 
their additional value first of all in a translational experimental 
setting. In other words, it seems less relevant that weight loss 
rates are similar in rats and patients after RYGB, as long as the 
weight loss is mediated by similar physiological mechanisms in 
both settings.
Most animal research has been performed with RYGB and 
VSG interventions in rats or mice. Although the effect sizes of 
RYGB and VSG operations were found to show quantitative 
differences, it appeared that qualitative changes were remark-
ably robust between different studies. In other words, variables, 
such as surgical technique, pre-, peri-, and postoperative diet, 
baseline weight, and level of adiposity which all may affect the 
study outcome, were found to have a surprisingly little effect on 
the general information gain of these studies [discussed in Ref. 
(23, 24)].
ANiMAL MODeLS OF BARiATRiC 
SURGeRY TeCHNiQUeS
Although surgical methods to reduce body weight were first intro-
duced more than 50 years ago and have been used in increasing 
frequency ever since, it is surprising that researchers only recently 
started to develop greater interest in post-bariatric physiological 
mechanisms. Koopmans and colleagues were among the first 
scientists who systematically used animal models to investigate 
the underlying mechanisms of bariatric surgery. These authors 
were able to demonstrate that a method called ileal transposition 
was not only effective in treating both genetic and hypothalamic 
lesion-induced obesity in rats, but also that the loss of body weight 
and body fat was associated with a reduction in eating. They fur-
ther observed that ileal transposition caused hypertrophy of the 
small intestine and concluded that the early contact of the distal 
small intestine with undigested food and digestive enzymes may 
lead to an increased release of gastrointestinal hormones as one 
mediating factor (25–30).
Two other groups also made early contributions to the cur-
rent literature of rodent models of bariatric surgery. Atkinson 
and Brent demonstrated that blood circulating factors seem 
to be critical for the reduction in eating after intestinal bypass 
operations in rats (31), and Meguid et al. were among the first to 
study altered brain signaling post-RYGB (32, 33). More recent 
studies built on these seminal experiments and the explanations 
how bariatric surgery and in particular RYGB reduce eating 
and body weight are still manifold. Finally, only a few groups 
published research with models of the AGB [e.g., Ref. (11)], 
and even less animal research has been done using the MGB 
technique (12).
RYGB AND vSG iN RATS AND MiCe
The interest of the scientific community in post-bariatric physiol-
ogy has grown exponentially over the last decade and many groups 
contributed significantly to the growing knowledge regarding 
the underlying mechanisms of bariatric surgery by using animal 
models of RYGB and VSG [e.g., Ref. (9, 10, 24, 34–55)]. Many of 
the reported effects showed striking similarities to what has been 
observed in RYGB or VSG patients.
For example, RYGB and VSG in rats and mice typically 
induced a rapid and sustained body weight loss which was 
mainly due to a reduction in body fat mass (40, 51, 56, 57). Post-
surgical weight loss correlated to a large extent with reduced 
spontaneous eating, but an increase in energy expenditure may 
also play a role (51, 57, 58).
In addition, animal models also provided compelling argu-
ments against traditional concepts such as intestinal malabsorp-
tion and mechanical restriction. There is nowadays a large body 
of evidence indicating that neither malabsorption nor restriction 
are the only mechanisms that exclusively explain the overall 
reduction in caloric intake and body weight after bariatric sur-
gery (10, 51). In regard to caloric malabsorption, both animals 
and patients are able to digest and absorb ingested nutrients to a 
similar extent after RYGB than their respective controls. However, 
some reduction in fat digestibility has been described in rats and 
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mice after RYGB when postoperatively exposed to a high-fat 
diet (35, 57), and a recent study indicated that intestinal glucose 
absorption may also be reduced after RYGB as a consequence of 
reduced sodium delivery and sodium-dependent glucose absorp-
tion in the proximal parts of the reconstructed small intestine 
(59). Thus, some role of maldigestion and malabsorption for body 
weight loss after RYGB needs to be considered in this scenario.
In regard to mechanical restriction, various studies have 
shown that RYGB- or VSG-operated rats and mice are indeed 
able to ingest larger quantities of food if they are metabolically 
challenged, e.g., subsequent to temporary food restriction after 
surgery (10, 24) or during lactation in female reproducing ani-
mals (60). Other arguments against a major impact of mechanical 
restriction on reduced eating after RYGB surgery include the 
observation that RYGB rats do not increase prandial drinking 
that might suggest an attempt to overcome mechanical constraint 
through food dilution with water. Furthermore, food intake after 
RYGB can be increased in rats and humans by somatostatin 
analogs that block the release of gastrointestinal hormones but 
which do not alter the mechanical situation post-RYGB (61, 62). 
In addition, differences in food intake and body weight are not 
related to the size of the gastro-jejunostomy in RYGB rats (63).
It needs to be emphasized that it was certainly wrong to 
explain the observed changes in eating behavior after bariatric 
surgery entirely and exclusively with mechanistic concepts, such 
as restriction and malabsorption, but it might be equally incor-
rect to neglect their impact. A typical finding after both RYGB 
and VSG operations is a change in meal pattern. Similar to RYGB 
patients, rats typically eat smaller meals after RYGB, which is 
partly compensated by an increase in meal frequency. In more 
detail, the size of nocturnal meals has been found to be markedly 
reduced post-RYGB, while the size of diurnal meals was actually 
increased compared to sham-operated control animals (23, 42, 
51, 64). Furthermore, even if RYGB or VSG rats are metaboli-
cally challenged leading to high levels of total food intake (e.g., 
temporary food restriction; pregnancy and lactation), the rats do 
not seem to increase their meal size (10, 24, 60). Finally, a recent 
study showed that increased intake induced by antagonizing mel-
anocortin-4 (MC4) receptors in the hypothalamus was entirely 
dependent on an increase in meal number, but not meal size (65). 
In summary, the available data indicate that RYGB (or VSG) rats 
may be mechanically restricted in a sense that the amount of 
food that can be eaten in a single meal is limited, but that rats are 
able to adapt to specific metabolic situations by increasing meal 
frequency.
MeCHANiSTiC STUDieS TO eXPLAiN 
ReDUCeD eATiNG AND weiGHT 
LOSS AFTeR RYGB AND vSG
Animal experiments provide valuable insight into the mecha-
nisms that are at play after bariatric surgery and that lead not 
only to a reduction of body weight but also to long-term mainte-
nance of the lower body weight. The available data indicate that 
RYGB- or VSG-operated individuals develop a new set point of 
their body weight that is defended even if challenged by certain 
experimental conditions (e.g., temporary food restriction or 
forced overfeeding).
Leptin may play an important role in the control of this set 
point defense because leptin-deficient ob/ob mice do not exhibit 
the same benefits in body weight and metabolic control compared 
to control animals unless leptin is replaced (66). Thus, the bariat-
ric surgery procedure itself may be most critical for the extent of 
weight loss until the newly defended body weight may be reached. 
This may also indicate that further temporary manipulations 
(e.g., additional calorie restriction, alterations in food composi-
tion) may not necessarily result in additional long-term benefits.
The latter point is also important in a different context. Various 
studies showed that RYGB and VSG may lead to an alteration in 
food preference with rats and patients choosing to eat less high-fat 
and sugary foods in favor of less energy dense alternatives when 
offered a choice (42, 53, 57, 67–69). However, a recent review 
of the human literature found that reported changes in dietary 
macronutrients after RYGB were modest and only transient in 
nature (70). Although alterations in dietary selection could 
conceivably contribute to improved glycemia and body weight 
after RYGB and VSG surgery, it remains unclear whether they 
represent an essential contributor to these beneficial effects after 
surgery or not. Based on the findings reported in the previous 
paragraph, this may actually not be the case, with the respective 
consequences for dietary counseling.
Roux-en-Y gastric bypass and VSG lead to characteristic 
changes in the concentration of gut hormones and bile acids 
(8, 41, 71–73), which is a robust phenomenon consistently 
reported in basically all published studies. Nevertheless it needs 
to be stated that most attempts to establish a causal role of gut 
hormones and bile acids for the post-bariatric outcome have 
failed so far. For example, data obtained from GLP-1 receptor 
knockout animals or using GLP-1 receptor antagonists are nega-
tive in that RYGB- or VSG-induced effects did not differ from 
wildtype control animals (43, 74–76). Thus, while changes in 
gut hormones alone cannot explain the RYGB- or VSG-induced 
effects, it appears that rather a combination of multiple physi-
ological alterations and interactions are at play. These include 
elevations in basal or postprandial concentrations of many gut 
hormones [GLP-1, cholecystokinin (CCK), amylin, peptide YY 
(PYY), etc.], increased levels, and altered composition of bile 
acids, as well as alterations in the diversity and composition of 
gut microbiota after bariatric surgery (7, 35, 41, 71, 76–78).
The large number of studies describing changes in the 
periphery after bariatric surgery contrasts with the remarkable 
paucity of data addressing changes in central nervous system 
function that may explain the effects of bariatric surgery. The 
most in-depth studies described the potential contribution of 
MC4 receptor signaling that is an important center point for the 
control of energy balance in general. The published data indicate 
that there may be a species difference in the relevance of MC4 
signaling, because VSG effects were still present in MC4-deficient 
rats (46). By contrast, RYGB-induced changes differed between 
MC4-deficient mice and respective controls, and there appeared 
to be a gene dosage effect (34, 44, 79). The latter may also explain 
why RYGB or VSG patients with mutations in the MC4 gene 
typically still respond to bariatric surgery because they do not 
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correspond to a full receptor knockout. Interestingly, some rare 
mutations in the MC4 were associated with a bigger weight loss 
and a faster resolution of diabetes post-surgery (80) [but see Ref. 
(81)]. Recent data indicated that RYGB also changes signaling in 
feeding areas of the caudal hindbrain in RYGB rats (82) but no 
equivalent human data are currently available.
Future experiments need to be designed to mimic specific 
aspects of bariatric surgery and to define the causal role of 
specific mechanisms for the beneficial effects of bariatric surgery. 
Manipulations may, e.g., include the local infusion of nutrients 
in specific gut segments, manipulations of nutrient contact with 
the gut mucosa, diversion of pancreatic juices and bile acids, and 
perhaps also the transposition of specific gut segments, similar to 
the procedure that Koopmans and colleagues had used more than 
30 years ago (25, 29, 30).
COMPARiSON OF ANiMAL MODeLS iN 
BARiATRiC SURGeRY ReSeARCH wiTH 
THe CLiNiCAL SiTUATiON iN HUMANS
The validity of animal model data depends on the similarities 
in phenomena and mechanisms between humans and animals. 
For the most part, it seems safe to say that the similarities largely 
outnumber potential differences that may be more quantitative 
than qualitative.
The key effect of bariatric surgery seems to be a loss of excessive 
fat mass by resetting the system of body weight control in both 
animals and humans (10, 56, 66). In humans, loss of excessive 
body weight is typically more pronounced in more obese patients 
(83). On the other hand, diabetic patients with a body mass index 
between 22 and 35 lose on average ~20% of their total weight 
after RYGB (84), which is markedly less than the typical weight 
loss in heavier patients. Interestingly, a similar phenomenon is 
seen in animals where post-RYGB body weight loss also seems to 
correlate with the degree of preoperative obesity. Obese OLETF 
rats, i.e., rats that are obese because they overeat due to the lack 
of functional CCK1 receptors, lost markedly more weight com-
pared to their lean LETO controls after RYGB (49), and recent 
studies in mice with different degrees of obesity corroborated 
these findings (56).
One aspect that differs between rodents and humans is the 
difference in weight growth curves; i.e., in contrast to obese 
humans, where the “control condition” typically refers to a 
stable body weight, control groups of rats or mice often gain 
weight over the observation period of a study. Here, the effect of 
bariatric surgery may be a prevention of this weight gain rather 
than an absolute weight loss. However, animal models allow 
the detailed study of major components contributing to the 
body weight loss in standardized and reproducible conditions, 
i.e., reduced caloric intake, increased energy expenditure, or 
reduced energy availability from ingested nutrients. By contrast, 
data on food selection and intake in humans rely in most cases 
on self-reported food intake that is vulnerable to inaccuracy for 
several reasons (70).
A further advantage of animal models is the use of specific 
control groups for reduced caloric intake or weight loss in respect 
to the metabolic consequences of bariatric surgery; in other 
words, pair fed or body weight matched controls, or controls for 
specific metabolic situations allow to distinguish bariatric sur-
gery effects that are specific to the surgical manipulations, such 
as the anatomical re-arrangement of the small bowel anatomy 
versus effects that are rather a consequence of the induced weight 
loss (23, 24, 50, 51, 71, 85).
As discussed, body weight loss after bariatric surgery is mainly 
due to reduced energy intake and changes in meal patterns (42, 
51, 64), and alterations in food choice and taste preference may 
also play a role (38, 42, 47, 53, 67, 69, 86). Further important simi-
larities between animal models and humans undergoing bariatric 
surgery include changes in the postoperative profile of gut hor-
mones and bile acids, but also the metabolic beneficial effects of 
bariatric surgery. The latter comprise, e.g., rapid improvements of 
insulin sensitivity, insulin secretory capacity, and cardiovascular 
function [e.g., Ref. (36, 45, 50, 71, 87–99)]. Similar to the effects 
on energy balance, a large number of follow-up experiments were 
performed to study the potential mechanisms underlying the 
metabolic effects of bariatric surgery. This included the manipula-
tion of hormone systems or signaling cascades, and some studies 
clearly indicated that changes induced by bariatric surgery, e.g., 
elevated GLP-1 levels, do contribute to post-surgery metabolic 
effects in rats and humans (71, 93). However, other studies 
revealed rather disappointing results in a sense that blockade of 
GLP-1 signaling was often not able to offset the effects of bariatric 
surgery (75, 76).
Another contributing factor to weight loss after bariatric in 
humans and animal models may be the change in complexity 
and diversity in the gut microbiota. RYGB and VSG alter the 
composition of the gut microbiota and transplantation studies 
indicate that these alterations may also play a causal role in the 
improved metabolic status after bariatric surgery (35, 73, 100). 
For example, by colonizing germ-free mice with stools from the 
patients, Tremaroli et al. demonstrated that the surgically altered 
microbiota promoted reduced fat deposition in recipient mice. 
Mice also had a lower respiratory quotient, indicating decreased 
utilization of carbohydrates as fuel, suggesting that the gut micro-
biota may play a direct role in the reduction of adiposity observed 
after bariatric surgery (101).
Finally, not only the beneficial but also the negative conse-
quences of bariatric surgery seem to be recapitulated in animal 
models, similar to what is seen in human patients. To give just 
three examples, RYGB causes a demineralization of the skeletal 
system potentially leading to an increased risk in bone fractures 
(85, 102–104). The underlying reasons for this effect are not 
clear, but own results indicate that a more acidotic status post-
RYGB leading to increased calcium release from the bone may 
play a role. Second, RYGB may increase the risk for excessive 
alcohol intake in patients (105, 106) – a behavior which was 
also found in rats that did not prefer alcohol before the surgical 
intervention. Third, even though the metabolic status improves 
markedly in most diabetic patients after RYGB, some patients 
were found to have large fluctuations of their blood glucose 
concentration after RYGB surgery, especially in the periprandial 
phase paralleled by prolonged episodes of hypoglycemia. Similar 
findings have been reported in rodent RYGB models. The reason 
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for these larger than normal glycemic fluctuations is not entirely 
clear, but may be linked to increased secretion of GLP-1 leading 
to a strong increase of insulin release which then may require 
the compensatory release of counterregulatory hormones. In 
other words, despite the markedly improved general metabolic 
status, the fine tuning of glucose control may not be achieved by 
RYGB (50, 107–111).
NOTeS OF CAUTiON ON THe USe OF 
ANiMAL MODeLS iN BARiATRiC 
SURGeRY ReSeARCH
Not all findings reported in rodent bariatric surgery models find 
their direct equivalent in the clinical situation, or vice versa, but 
some of the differences among species may be more quantitative 
than qualitative. Four examples will be discussed here.
First, the weight loss of RYGB and VSG in rats and mice is due 
to a reduction in eating and an increase of energy expenditure 
(respectively, the prevention of its decrease in weight-reduced 
animals). The relative importance of the energy expenditure 
component seems to be bigger in mice than rats; in fact, in some 
mouse studies, increased energy expenditure appeared to explain 
most of the surgery induced weight loss because food intake in 
RYGB-operated mice was higher than that in sham-operated 
controls (40, 51). By contrast, only some studies in humans report 
an increase in total energy expenditure. However, similar to the 
increased diet-induced thermogenesis that has been reported in 
rats, postprandial energy expenditure also seems to increase in 
some RYGB patients (55, 112–115).
The reason for the real or apparent species differences in 
respect to energy expenditure after RYGB is not clear but it 
may be more a general phenomenon of biology and physiology 
rather than a specific finding after bariatric surgery. The control 
of energy balance via energy expenditure may be much more 
efficient in mice with their large body surface to body mass ratio; 
in humans, this ratio is opposite, and this may be reflected in the 
more important control of energy balance via energy intake. Rats 
may be between both extremes, and this may explain why both 
energy intake and energy expenditure are typically affected by 
bariatric surgery in rats.
Second, bariatric surgery and in particular RYGB and VSG 
also lead to changes in food selection, and some reports claim that 
consumption of high-fat and sweet foods decreases post-RYGB 
(70, 116, 117). Similar findings have been reported in rats and 
mice because they chose to ingest lower amounts of high-fat or 
high-sugar diets than sham-operated controls. This decrease in 
intake is progressive and is reminiscent of a learning process 
(conditioned avoidance) (40, 42, 53, 57, 68). Interestingly, the 
decrease in sugar intake may also be due to an altered taste 
sensitivity because RYGB has been shown to lower the sucrose 
detection threshold in patients after RYGB (67) [see also Ref. 
(117, 118)]. Furthermore, brief access tests in rodents often did 
not indicate reduced avidity for sucrose or high fat and rats’ 
voluntary work for sucrose or lipid solutions is not decreased 
(119–122). Nonetheless, whether the findings in animal models 
can be directly translated into the human situation is not clear, 
and only few objectively assessed data in humans are available. 
Changes in macronutrient intake in rats seem to be a long-term 
effect, while lasting changes in relative macronutrient intake in 
humans have typically not been observed. In other words, it is 
not clear whether the proportion of fat in the diet of post-RYGB 
individuals is decreased over extended periods of time, and it is 
also not clear if and for how long changes in diet composition 
contribute to reduced energy intake and weight loss in RYGB-
operated patients.
Third, a typical finding in RYGB-operated rats is a massive 
hypertrophy of the intestinal wall in the Roux limb and to a 
lesser extent in the common channel of the RYGB reconstruction 
(51, 77, 123–125). The hypertrophic small intestinal epithelium 
may contribute to the increase in total energy expenditure in 
rats, and it may contribute to sufficient nutrient digestibility and 
absorption despite the altered gut anatomy. Whether the human 
gut hypertrophies to a similar extent in RYGB patients is still a 
matter of debate and only few well-controlled studies have been 
performed. One recent study, however, clearly indicated that the 
small intestine in RYGB patients showed a clear hypertrophic 
response (126). Furthermore, anecdotal evidence also reports 
that gut hypertrophy may also occur in RYGB patients; in a rather 
dramatic recent case, a short common channel was associated with 
massive mucosal hypertrophy eventually leading to a functional 
ileus (personal observation, Marco Bueter). The general extent 
and underlying mechanisms of gut hypertrophy post-bariatric 
surgery will need to be defined in further well-controlled clinical 
studies.
Finally, potential influences of anatomical differences between 
rodents (or other animal models) and humans need to be con-
sidered even though evidence for an important impact of these 
differences on study outcome is limited. The gastrointestinal 
anatomy differs between humans and rodents in some aspects. 
Mice, e.g., have an extensive portion of their stomach covered 
by cutaneous mucosa (called “forestomach” by some), and the 
proventriculus in rats also has no human equivalent. Furthermore, 
mice but not rats have a gall bladder. Despite that, delivery of bile 
into the proximal small intestine is also dependent on CCK in rats 
and no principal difference seems to exist between mice, rats, or 
humans in respect to the elevation of circulating bile acids after 
RYGB and VSG (8, 59, 71, 73, 88, 127–130). Of note, there are also 
some differences in the bile acid profile post-RYGB in humans 
compared to rat or pig RYGB models. Some bile acid species, 
such as the free bile acids cholic acid, chenodeoxycholic acid, and 
deoxycholic acid were similarly increased, but glyco-conjugated 
bile acid species concentrations depended on the animal model, 
and no global increase in tauro-conjugated species was observed. 
These differences may be relevant because different bile acid 
species have different affinity and efficacy at the various bile acid 
receptors (130).
MODeLS OF BARiATRiC OPeRATiONS 
OTHeR THAN RYGB AND SG
Mini-Gastric Bypass
Knowledge from previous experiments can now be used for 
the optimized design to study mechanisms of more recently 
introduced bariatric surgery procedures. The so-called MGB 
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has gained some interest because it has the reputation to be 
an easier version of the classical RYGB. However, very little 
information about possible mechanisms of action is available. 
More importantly, data about the long-term effects and potential 
negative consequences are not available so far. Interestingly, this 
technique has been reported to lead to an increase rather than a 
decrease in eating. Energy expenditure has not been studied in 
detail after MGB, but it is generally assumed that maldigestion 
and malabsorption may be important components in the weight 
lowering effect of MGB (12, 13, 131, 132). If the latter were the 
case, the mechanisms of action would clearly differ between 
RYGB and MGB and would put a note of caution on the use 
of the MGB due to the potential of developing deficiencies in 
essential nutrients.
Biliopancreatic Diversion
The biliopancreatic diversion (BPD) introduced and developed 
by Scopinaro consists of a partial gastrectomy with a Roux-en-Y 
gastro-jejunostomy forming an alimentary limb and a duodeo-
jejunal biliopancretic limb anastomosed to the distal ileum. The 
operation leads to significant weight loss with normal absorp-
tion of bile salts, water and electrolytes (133). This operation is 
generally performed in much lower numbers than RYGB and SG 
and has its main indication in severely and mega-obese patients 
(19). Rat models of BPD revealed that serum protein, cholesterol, 
and triglycerides fell by 25–40% postoperatively (134), while the 
procedure was associated with intestinal hypertrophy and with 
increased GLP-1, GLP-2, and PYY levels (135).
Biliopancreatic Diversion with 
Duodenal Switch
To preserve physiologic gastric emptying and to prevent anasto-
motic ulcer after BPD by decreasing the effects of alkaline biliary 
reflux, Hess developed a modified BPD procedure with the 
alimentary limb being directly anastomosed to the post-pyloric 
duodenum (136). This operation is today known as BPD with 
duodenal switch (BPD-DS) and also includes a VSG, before the 
use of VSG as a stand-alone procedure (137). The BPD-DS is con-
sidered by some as the most efficient surgery in treating obesity 
and T2DM, but the rate of early complications is higher and it 
might also be associated with a higher perioperative mortality 
(138); for this reason, the BPD-DS is not extensively performed 
worldwide (19). BPD-DS operations in rats showed that the 
procedure is associated with an increased fecal energy loss as 
well as a (compensatory) intestinal hypertrophy with elevated 
levels of fasting and postprandial plasma GLP-1 and PYY (139), 
while there is a reduced expression of thermogenic genes in the 
interscapular brown adipose tissue (140).
OUTLOOK AND CONCLUSiON
Overall, rat and mouse experiments in bariatric surgery have 
been proven to be an important and relevant research tool that 
has led and will lead to important findings translatable into 
the clinical situation. Some differences have been identified, 
but careful experimental designs still allow clinically relevant 
conclusions. More studies are needed that directly compare 
effects and consequences of bariatric surgery procedures across 
species. This includes the assessment of similar parameters 
pre- and post-bariatric surgery in human patients and animal 
models, but also similarly designed experiments that yield 
mechanistic information in all relevant species. Only few exam-
ples are available in the literature [e.g., Ref. (67, 70, 121, 122, 
129, 130)]. Nonetheless, without animal models, our knowledge 
on how bariatric surgery works (or may not work!) would be 
very limited and the vast literature that is available indicates 
that most animal models seem to recapitulate remarkably well 
the findings in humans. Future research in animal models of 
bariatric surgery will most likely include the more frequent use 
of larger animal models, e.g., minipigs or dogs (129, 141, 142). 
Larger animals offer significant advantages compared to rats and 
mice; e.g., larger blood volumes can be collected over extended 
periods of time, and specific interventions in defined parts of the 
gastrointestinal tract may be easier to perform in larger animal 
models. Furthermore, specific aspects of energy expenditure 
may be more similar to humans in larger animals compared to 
small animals, in particular the mouse.
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